S&P/ASX All Ords Index (ASX: XAO) shares are 0.9% lower at 9,115.5 points on Tuesday.
With earnings season over, brokers have updated their ratings and 12-month price targets on hundreds of ASX shares.
Here are six stocks with strong upside potential.
Image source: Getty Images
NextDC Ltd (ASX: NXT)
The NextDC share price is $12.46, down 2.3% today.
Over the past month, this ASX tech share has fallen 14%.
UBS has a buy rating on NextDC shares with a $23.45 target.
This suggests a potential 88% upside ahead.
Nine Entertainment Co. Holdings Ltd (ASX: NEC)
The Nine Entertainment share price is 86 cents, down 3.2% today.
Over the past month, this ASX communications share has dropped 15%.
Morgan Stanley has a buy rating on Nine shares with a 12-month target of $1.40.
This suggests a potential 63% upside ahead.
Qantas Airways Ltd (ASX: QAN)
The Qantas share price is $9.30, down 0.3% today.
This ASX travel share has fallen 11% over the past month.
Morgan Stanley has a buy rating on Qantas shares with a $12.80 target.
This implies potential capital growth of 38% over the next year.
Centuria Capital Group (ASX: CNI)
The Centuria Capital Group share price is $1.33, up 3.7% today.
Over the past month, this ASX real estate investment trust (REIT) has fallen 11%.
MA Financial Group has a buy recommendation on Centuria Capital Group shares with a $1.83 target.
This indicates potential capital gains of 38% over the next year.
Paladin Energy Ltd (ASX: PDN)
The Paladin Energy share price is $11.61, down 0.9% today.
Over the past month, this ASX uranium share has spiked 12%.
Canaccord Genuity has a buy call on Paladin Energy shares with a $15.80 target.
This suggests a potential 36% upside ahead.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is $168.81, up 0.1% today.
Over the past month, this ASX healthcare share has fallen 4%.
Bell Potter has a buy rating on Pro Medicus shares with a $226 target.
This indicates capital gains of 34% over the next year.
In a note, the broker commented:
PME reported FY26 revenue and EBIT growth of 23% and 26% respectively with the result at EBIT modestly (1.5%) ahead of consensus earnings.
As the revenue base of the group expands the top line growth is decelerating, however, margin expansion continues and this drove the small earnings beat.
FY26 EBIT margin expanded by a further 190bps to 75% and is likely to continue at this rate for the foreseeable future.
